Wegovy 2.4mg Dose

Reaching the 2.4mg weekly dose is an important moment. It usually means you’ve completed your dose escalation phase and your body has adapted to treatment.

At this point, two questions naturally come up:

• “Should I move up from 1.7mg to 2.4 mg?”
• “Once I’m here, how long do I stay on it, and what happens next?”

This guide answers both, based on real clinical guidance from NICE, research from the STEP trials, and Medicspot’s experience supporting thousands of UK patients on GLP-1 treatments.

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural gut hormone helping regulate appetite, fullness, and blood sugar.¹

The 2.4mg weekly dose is the maintenance dose – the highest approved level for weight management in the UK.² It’s designed for long-term use once you’ve gradually stepped through the doses:

1. Wegovy 0.25mg
2. Wegovy 0.5mg
3. Wegovy 1mg
4. Wegovy 1.7mg
5. Wegovy 2.4mg

This calculator uses data from a major clinical study on GLP-1 weight loss treatment to show what typical progress looks like. Your results will depend on your specific medication, dose, lifestyle, and medical history.

Moving from 1.7mg to 2.4mg is often the next step, but it’s not for everyone. Your decision depends on three things:

1. Tolerability

If you’re comfortable on 1.7mg with minimal nausea or bloating, you’re likely ready to increase. If side effects are still noticeable, your prescriber may advise staying at 1.7mg a bit longer before moving up.

2. Progress

Clinical guidance suggests reviewing progress at each stage. If weight loss has slowed or plateaued, the 2.4mg dose may help you reach your next goal.

3. Clinical review

Our clinicians check:

• Whether you’ve reached a healthy BMI range or still need active weight loss
• If anything has changed on your NHS Summary Care Record (SCR)
• Your tolerability and motivation to continue lifestyle changes

Once you reach 2.4mg weekly, the focus shifts from dose escalation to weight maintenance.

How your body responds

In large STEP trials, people on 2.4mg plus lifestyle support lost an average of 15% of their body weight over 68 weeks.³ Most continued to see slow, steady loss before reaching a healthy plateau.

Appetite is usually more stable, cravings drop, and many describe “thinking about food less.” This mental freedom is a major benefit of reaching maintenance.

How long you stay on it

NICE guidance and NHS specialist services recommend regular review at around 2 years to decide whether continuing makes sense for you.⁴ Some patients may stay on Wegovy longer for weight-maintenance if clinically appropriate.

What changes at this stage

• Weight loss usually slows – and that’s expected.
• You may see more focus on behaviour change with your coach.
• Side effects like nausea often improve significantly after stabilisation.

The goal of maintenance is to help your body defend its new lower weight and prevent regain.

Why this matters

When weight drops, metabolism and appetite hormones try to push it back up.⁵ Wegovy helps “hold the line” by reducing that drive to eat more.

What helps long-term success

• Keep your weekly injection day consistent (helps routine).
• Stick to a balanced, protein-rich diet to protect muscle.
• Stay hydrated and active – even 10-minute walks add up.
• Keep in touch with your coach. Accountability is key.

At Medicspot you’ll also have regular check-ins to review progress, side effects and motivation.

You and your Medicspot clinician will review treatment regularly. You might pause or stop if:

• Weight loss is <5% after 6 months⁷
• You can’t tolerate side effects despite adjustments
• You’ve reached your goal and are ready to transition off medication

If treatment stops, your coach will support you to reduce weight regain.

What to look out for

Mild side effects are normal and to be expected. If you feel your symptoms are more severe than you expected or you are concerned please contact us.

We would always want to know about stomach pains that feel a little more than a mild discomfort or if you start feeling unwell. Any unusual redness or discharge from your injection site is also something to look out for.

Reaching the 2.4mg Wegovy dose is something to be proud of. It means you’ve already put in the work, through patience, consistency, and the courage to make a change.

The habits you build now (how you eat, move, sleep, and manage stress) will shape your long-term results. The medication gives you a helping hand, but the power to keep the weight off comes from the changes you make every day.

At Medicspot, we’re here to make sure you’re supported through every step. Your prescriber reviews your progress, your health coach checks in regularly, and our team is always on hand if you need help with side effects, plateaus, or motivation.

¹ Scottish Medicines Consortium. “Semaglutide (Wegovy®) for weight management.” Final Advice (2022). Last accessed Oct 2025. [https://scottishmedicines.org.uk/media/7864/semaglutide-wegovy-final-dec-2022-amended-010923-for-website.pdf]

² Wegovy. Wegovy dosing schedule. Last accessed October 2025. [https://www.wegovy.com/taking-wegovy/dosing-schedule.html]

³ New England Journal of Medicine. “STEP 1 Trial Summary. Once-weekly semaglutide in adults with overweight or obesity.” (2021). Last accessed October 2025. [https://www.nejm.org/doi/full/10.1056/NEJMoa2032183]

⁴ NICE. Guidance TA875: Semaglutide for managing overweight and obesity (2023). Last accessed Oct 2025. [https://www.nice.org.uk/guidance/ta875]

⁵ Sumithran P. et al. “Long-term persistence of hormonal adaptations to weight loss.” New England Journal of Medicine (2011). Last accessed October 2025. [https://www.nejm.org/doi/full/10.1056/NEJMoa1105816]

⁶ Medicines.org.uk. Wegovy patient information leaflet. Last accessed October 2025. [https://www.medicines.org.uk/emc/product/13800/pil]

⁷ NICE. Technology Appraisal draft FAD TA875 criteria (2023). Last accessed October 2025. [https://www.nice.org.uk/guidance/gid-ta10765/documents/final-appraisal-determination-document]

⁸ Wilding J.P.H. et al. “STEP 1 Extension Study – Weight regain after withdrawal of semaglutide.” Diabetes, Obesity and Metabolism (2022). Last accessed October 2025. [https://pubmed.ncbi.nlm.nih.gov/35441470/]

GOV.UK. GLP-1 receptor agonists: reminder of the potential side-effects and misuse risk. UK Drug Safety Update (2023). Last accessed October 2025. [https://www.gov.uk/drug-safety-update/glp-1-receptor-agonists-reminder-of-the-potential-side-effects-and-to-be-aware-of-the-potential-for-misuse]

Diabetes UK. Wegovy and GLP-1 medications – how they help with weight loss. Last accessed October 2025. [https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/treatments/tablets-and-medication/glp-1/semaglutide/wegovy]

NHS England. Weight-management injections. Last accessed October 2025. [https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/]

This article is for general information only and should not be used for the diagnosis or treatment of medical conditions. Medic Spot Limited has used all reasonable care in compiling the information but makes no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. In the event of an emergency, please call 999 for immediate assistance.

There is no guarantee of a specific weight loss medication being prescribed. Clinicians will review your online questionnaire and will recommend the most appropriate weight loss treatments for you based on your answers. In some cases the clinicians may contact you for additional information. See our Terms of Service for more information.